Navigation Links
Halozyme Therapeutics Announces Implementation of Development Focused Strategy
Date:10/11/2010

SAN DIEGO, Oct. 11 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced a focusing of its resources on advancing its core proprietary programs through key clinical inflection points in 2011 and 2012, and supporting strategic alliances with Roche and Baxter such as validation of Halozyme's commercial scale manufacturing process to produce kilogram quantities of enzyme. Halozyme will continue full development of its Phase 2 Ultrafast Insulin, Phase 1 PEGPH20, and preclinical HTI-501 programs, but will decrease research relating to the discovery and preclinical assessment of new compounds, resulting in a reduction in the workforce of approximately 25 percent. The company expects to incur a one-time charge in the fourth quarter related to the workforce reduction that will be mostly offset by reduced payroll expenses during the quarter. The implementation of this strategy is not expected to impact previous net cash burn guidance, and management reiterates its guidance of $40 to $45 million of net cash burn for 2010.  

(Logo:  http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100302/LA63139LOGO)

"A decade's worth of investment in discovery and preclinical research from 2000 to 2010 has resulted in two FDA approved products, three late stage product candidates with Roche and Baxter, and three exciting proprietary programs with best-in-class or first-in-class potential," stated Jonathan Lim, M.D., president and CEO. "This development focused strategy combined with our partners' achie
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Halozyme Therapeutics to Host Analyst Meeting on October 14 in New York
2. Halozyme Therapeutics Announces Public Offering of Common Stock
3. Halozyme Provides HYLENEX® Product Reintroduction Update
4. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
5. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
6. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
7. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
8. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
9. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
10. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
11. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014 Integrated Silicon Solution, ... advanced memory and analog IC solutions, today announced that ... July 24, 2014, at 7:00 a.m. Pacific Time (10:00 ... for the fiscal 2014 third quarter ended June 30, ... telephone, dial 1-888-556-4997 before 6:50 a.m. Pacific time on ...
(Date:7/10/2014)... , July 10, 2014  Valeant Pharmaceuticals International, Inc. ... announced it has completed the sale to Galderma of ... owned or held by Valeant for $1.4 billion in ... S.A, which recently completed its acquisition of Galderma. ... of our products to a company that is firmly ...
(Date:7/10/2014)... WOONSOCKET, R.I. , July 10, 2014 CVS ... its board of directors has approved a quarterly dividend of ... The dividend is payable on August 1, 2014, to holders ... Caremark CVS Caremark is dedicated to helping ... integrated pharmacy company in the United States ...
Breaking Medicine Technology:
(Date:7/11/2014)... surgery to repair damage to the anterior cruciate ligament (ACL) ... -- could increase a young athlete,s risk for further injuries, ... patients, aged 8 to 16, who had ACL reconstruction surgery. ... after their injury, 37 had surgery six to 12 weeks ... after their injury. The youngsters who had surgery later ...
(Date:7/11/2014)... CA (PRWEB) July 11, 2014 Ticket ... Bryan Tickets at the Sleep Train Amphitheatre in Wheatland, ... venues that can compare to what the Sleep Train Amphitheatre ... musical events and special attractions over the course of its ... 16th, the Sleep Train Amphitheatre in Wheatland (Sacramento metro area) ...
(Date:7/11/2014)... The “Proteomics Market by Technology (Protein Microarray, Mass ... X-ray Crystallography) - Instruments, Reagents & Services - ... major market drivers, restraints, and opportunities in North ... World (RoW). , The proteomics market has experienced ... due to the increasing need of proteomic outcomes ...
(Date:7/11/2014)... who screened positive for a history of hazardous or ... 50 percent after receiving mobile phone text messages following ... study published online yesterday in Annals of Emergency ... Young Adult Emergency Department Patients: A Randomized Clinical Trial ... 50,000 adults ages 18 to 24 visit ERs and ...
(Date:7/11/2014)... By Steven Reinberg ... -- Stress, hostility and depression may increase the risk for ... depression seemed to raise the risk of a stroke or ... also found that stress apparently raised stroke or TIA risk ... said. A TIA is a mini-stroke caused by a temporary ...
Breaking Medicine News(10 mins):Health News:Delaying Kid's Knee Surgery Could Be a Bad Play, Study Finds 2Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 2Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 3Health News:Proteomics Market Worth $20,696.4 Million by 2018 - New Report By MarketsandMarkets 2Health News:Proteomics Market Worth $20,696.4 Million by 2018 - New Report By MarketsandMarkets 3Health News:Proteomics Market Worth $20,696.4 Million by 2018 - New Report By MarketsandMarkets 4Health News:Text message medicine: Texts from the ER can reduce binge drinking 2Health News:Stress, Depression May Boost Stroke Risk, Study Finds 2Health News:Stress, Depression May Boost Stroke Risk, Study Finds 3
... SCHAUMBURG, Ill., May 12 For the estimated ... important fashion accessory,that many women wear, and change, daily. ... more than they bargained for when purchasing,inexpensive earrings. Nickel ... on the earlobes and repeated exposure can make treatment,difficult., ...
... investigation after efforts uncover ... system abuse, ... New York State in 2007. With so many recipients and,providers involved, the ... fraud, waste, and abuse., Over the last two years, Salient Corporation, ...
... for event -, MCLEAN, Va., May 12 ... more effective than real, live dogs or cats ... other aging-related,illnesses?, Come find out Monday, June ... Community (VHRC) in McLean, Va., hosts an industry ...
... its,Distinguished Americans series, the U.S. Postal Service released ... Edward Livingston Trudeau (1848-1915), the,founder and first president ... of Tuberculosis, the precursor to the American Lung ... treating tuberculosis, a,highly infectious disease that at one ...
... Indoor Air Professionals advises consumers on indoor air quality, ... Asthma Awareness Month,according the Environmental Protection Agency (EPA), and ... consumers on the,importance of clean indoor air in relation ... nearly 2 million Americans to the emergency,room in the ...
... earn both national, ... state kudos, SOUTHFIELD, Mich., May 12 ... Care Network of,Michigan., BCN is one of 20 companies worldwide receiving the ... the second year,in a row BCN has earned the annual award. On May ...
Cached Medicine News:Health News:Study Finds Nearly One-Third of All Inexpensive Earrings Examined Tested Positive for Nickel 2Health News:Study Finds Nearly One-Third of All Inexpensive Earrings Examined Tested Positive for Nickel 3Health News:Study Finds Nearly One-Third of All Inexpensive Earrings Examined Tested Positive for Nickel 4Health News:Salient Corporation's Performance Management Solution Helps NY State Counties Identify Medicaid Fraud, Waste, and Abuse 2Health News:Paro, the World's Only Robotic Baby Harp Seal - Designed Specifically for Therapy - to be Focus of Industry Event at Vinson Hall Retirement Community in McLean, Va., June 2 2Health News:American Lung Association Founder Honored With New U.S. Postage Stamp 2Health News:Asthma Awareness Month Spawns Healthy Advice 2Health News:Blue Care Network of Michigan Named a Great Workplace by Gallup, MBPA 2Health News:Blue Care Network of Michigan Named a Great Workplace by Gallup, MBPA 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... used in the ARED study, as well ... which suggested no AMD disease progression in ... period. Macula Complete also contains efficacious amounts ... support the mitochondria, as well as to ...
... MacularProtect delivers levels of ... vision and macular health in ... by The National Eye Institute. ... of lutein, an antioxidant found ...
... is a scientifically advanced nutritional formulation ... and full body health. MacularProtect Complete ... trial and other advanced research. It ... provides a broad foundation of antioxidants, ...
Medicine Products: